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tTATE-OF-THE-ART PAPER969Antithrombotics in Acute Coronary Syndromesarc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson,
ars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano
onaca and colleagues review the optimal combinations of antithrombotic therapies, their
iming, and the appropriate targeted subgroups to produce maximal thrombotic efficacy while
educing the risk of hemorrhagic complications in patients with acute coronary syndromes
ACS). The efficacy and safety data for the most commonly used drugs are reviewed
ncluding heparins, glycoprotein IIb/IIIa inhibitors, antithrombins, factor Xa inhibitors, and
ntiplatelet agents. Integrating the new data into treatment guidelines is complicated by
ifferent efficacy and safety end points and the variability in study populations and presenting
yndromes. In many situations there is a lack of data, or conflicting data, leading to questions
nd controversies that will hopefully be resolved when the results of ongoing trials are
vailable.VIEWPOINT IEWPOINT985Delivery System Reform Needs More Input From Physiciansames T. Dove, W. Douglas Weaver, Jack Lewin
n a viewpoint paper, Dove, Weaver, and Lewin address proposals currently being reviewed
y Congress to create a more integrated health care delivery system. Such a system has the
otential to reduce, or at least constrain, medical costs by reducing duplication of diagnostic
rocedures and potentially by changing provider reimbursement from procedure- or service-
ased to capitation-based. Accountable care organizations (ACOs) is the terminology
or these integrated systems. The ACO structure is complicated; it appears to require
artnerships between hospitals and physicians, raising concerns that hospital-led
COs will force physician employment by hospitals. The authors argue that patients,
hysicians, and payers are in a better position to guide the redesign of the health care
elivery system than government agencies, policy organizations, or elected officials. They
onclude with the statement: “We strongly believe—and the ACC has proclaimed—that
hange in health care delivery must be accomplished with patients and physicians at the
able.”(continued on page A-20)
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989andated Coronary Angiography May Improve Long-Term Outcomes in
Medium- to High-Risk Patients Scheduled for Major Vascular Surgeryario Monaco, Paolo Stassano, Luigi Di Tommaso, Paolo Pepino, Arturo Giordano, Giovanni B. Pinna,
abriele Iannelli, Giuseppe Ambrosio
onaco and colleagues randomized over 200 patients scheduled for elective surgical treatment
f major vascular disease to either a standard pre-operative evaluation, where coronary
ngiography was performed based on the results of noninvasive tests, or a systematic strategy,
here all patients underwent pre-operative coronary angiography. Both groups were
evascularized as needed, and surgery was delayed for at least 30 days in those who underwent
ither bare-metal stenting or bypass surgery. Nearly 60% of the systematic group was
evascularized prior to the surgery, compared with 40% in the standard group. The in-
ospital major adverse cardiovascular event rate was slightly, but not significantly, lower in the
andatory group. However, at 5 years there was a significant reduction in mortality in those
ho were mandated to angiography. In this study, a strategy of routine coronary angiography
ositively impacted long-term outcomes in patients referred for vascular surgery.ditorial Comment: Giora Landesberg, Morris Mosseri, p. 997EART RHYTHM DISORDERS999Safety of Long-Term Anticoagulation in Patients Older Than 80 Yearsaniela Poli, Emilia Antonucci, Elisa Grifoni, Rosanna Abbate, Gian Franco Gensini, Domenico Prisco
rolonged longevity is leading to an increased need for stroke prevention in atrial fibrillation
AF) patients age 80 years, but the safety in very elderly patients has been questioned. Poli
nd colleagues conducted a prospective observational study on 783 AF patients on oral
nticoagulant treatment (OAT) at a single clinic devoted to the management of OAT.
atients spent a median of 14%, 71%, and 15% time below, within, and above the intended
herapeutic range, respectively. No difference in OAT quality was found between patients age
80 and 80 years. The overall rate of major bleeding complications was 1.4 per 100
atient/years. Patients age 80 years were twice as likely to have bleeding complications.
hese results indicate that the rate of major bleeding complications is higher in very elderly
F patients on OAT, but can be kept reasonably low if careful management of
nticoagulation is obtained.(continued on page A-24)
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aALVULAR HEART DISEASE1003Calculating Z Improves Risk Stratification in Patients With ASVa
eineb Hachicha, Jean G. Dumesnil, Philippe Pibarot
his study by Hachicha and colleagues examined the prognostic value of valvuloarterial
mpedance (Zva) in patients with aortic stenosis (AS). Zva estimates the global hemodynamic
oad faced by the left ventricle (LV) and is calculated by dividing the estimated LV systolic
ressure (systolic arterial pressure  mean transvalvular gradient) by the stroke volume
ndexed for the body surface area. Over 500 asymptomatic patients with at least moderate AS
aortic jet velocity 2.5 m·s1) were followed for total mortality, regardless of the realization
f aortic valve replacement. Four-year survival was significantly lower in the patients with a
aseline Zva 4.5 mm Hg·ml
1·m2 compared with those with Zva between 3.5 and 4.5 mm
g·ml1·m2 and those with Zva 3.5 mm Hg·ml
1·m2. Increased Zva is a marker of
xcessive LV hemodynamic load and may be useful to improve risk stratification and clinical
ecision making in patients with AS.ditorial Comment: Helmut Baumgartner, Catherine M. Otto, p. 1012PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH1014Injectable Hydrogel May Limit Post-MI RemodelingAlginate biomaterial 
(white) in infarct (2h 
aer injecon)onathan Leor, Shmuel Tuvia, Victor Guetta, Ferenc Manczur, David Castel, Udi Willenz, Örs Petneha´zy,
atali Landa, Micha S. Feinberg, Eli Konen, Orly Goitein, Orna Tsur-Gang, Mazal Shaul, Lea Klapper,
madar Cohen
his study tested the hypothesis that a hydrogel injected into the infarct-related artery a few
ays post-infarction could constrain the myocardium from expanding, thereby limiting left
entricular (LV) remodeling by providing temporary physical support to the damaged cardiac
issue. Leor and colleagues prepared a calcium cross-linked alginate solution that undergoes
iquid to gel phase transition. In a swine model of anterior myocardial infarction (MI),
lginate solution or saline was injected selectively into the infarct-related coronary artery.
xamination of hearts harvested after injection showed that the alginate crossed the infarcted
ndothelium and was deposited as hydrogel in the infarcted tissue. This prevented and even
eversed the LV enlargement seen in control animals. Further experiments showed that the
aterial did not provoke thrombotic complications either locally or remotely. These results
uggest that intracoronary injection of alginate biomaterial may prevent adverse remodeling
fter MI.(continued on page A-26)
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1024NP Gene Mutation Results in a Novel Peptide
With Useful Cardiovascular and Renal Effectsaul M. McKie, Alessandro Cataliotti, Brenda K. Huntley, Fernando L. Martin, Timothy M. Olson,
ohn C. Burnett, Jr
he cardiac hormone atrial natriuretic peptide (ANP) is a 28-amino acid (AA) peptide
hat consists of a 17-AA ring structure together with a 6-AA N-terminus and a 5-AA
-terminus. A mutation in the gene was identified from a cohort with familial atrial
brillation, which produces a 40-AA peptide consisting of native ANP (1-28) and a C-
erminal extension of 12 AA. McKie and colleagues named this peptide mutant atrial
atriuretic peptide (mANP), and herein report on its physiologic actions. In cultured cardiac
broblasts, ANP and mANP produced incremental increases in 3=,5=-cyclic guanosine
onophosphate. In a dog model, high-dose mANP produced significantly greater diuretic,
atriuretic, renin-angiotensin-aldosterone system inhibiting, cardiac unloading, and blood
ressure-lowering properties compared with native ANP. These results suggest that mANP
xerts greater and more sustained natriuretic, diuretic, glomerular filtration rate, and renal
lood flow-enhancing actions than native ANP.ditorial Comment: Adolfo J. de Bold, p. 1033
